Figure 3 (IMAGE)

Kanazawa University

Figure 3

Caption

Kaplan-Meier analyses of overall survival following <sup>131</sup>I-MIBG therapy: a period between initial diagnosis and <sup>131</sup>I-MIBG therapy, b with or without pain at <sup>131</sup>I-MIBG therapy, c with or without VMA and/or HVA elevation at <sup>131</sup>I-MIBG therapy, d initial overall response following <sup>131</sup>I-MIBG therapy. <i>MIBG</i> metaiodobenzylguanidine, <i>VMA</i> vanillymandelic acid, <i>HVA</i> homovanillic acid.

Credit

Kanazawa University

Usage Restrictions

The image may only be used with appropriate caption and credit.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.